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Understanding the aging process is central to preventing 
age-related disease burden and premature mortality. 
Many different measures have been suggested as having 
prognostic value for mortality.  Cellular aging may offer 
insights into organismic aging relevant to chronic 
diseases such as cardiovascular disease (CVD).  
Telomeres, the protective nucleoprotein structures 
capping the ends of eukaryotic chromosomes, can serve 
as markers of al.  
With  every  cell  division,  a  
 mitotic cell age and  replicative  potenti
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Abstract:  Telomere  length  (TL)  has  been  proposed  as  a  marker  of  mitotic  cell  age  and  as  a  general  index  of  human
organismic  aging.  Short  absolute  leukocyte  telomere  length  has  been  linked  to  cardiovascular‐related  morbidity  and
mortality.   Our aim was  to  test whether  the  rate of  change  in  leukocyte TL  is  related  to mortality  in a healthy elderly
cohort.   We examined a  subsample of 236  randomly  selected Caucasian participants  from  the MacArthur Health Aging
Study  (aged 70  to 79 years).   DNA  samples  from baseline and 2.5 years  later were assayed  for mean TL of  leukocytes.
Percent  change  in TL was  calculated as a measure of TL  change  (TLC).     Associations between TL and TLC with 12‐year
overall  and  cardiovascular mortality were  assessed.   Over  the  2.5  year  period,  46%  of  the  study  participants  showed








portion of the telomere cap is not replicated due to the 
“end replication problem” – that is, DNA polymerase 
does not completely replicate the end of a DNA strand  
[1].  Hence, cells in certain older organisms, including 
humans, have shorter telomeres on average than cells in  
younger organisms.   
 
Telomere length change (TLC) depends on many 
factors, prominent among them the rate of cell divisions 
and level of telomerase, a cellular ribonucleoprotein 
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reverse transcriptase enzyme that replenishes telomeric 
DNA and thus lengthens the telomere.  In cells lacking 
sufficient levels of telomerase, telomeres progressively 
shorten with successive cell divisions.  If the telomere 
shortening represents a clock ticking forward on cells’ 
lifespans, telomerase can slow or reverse this clock [2], 
making the two an intricately interdependent dynamic 
system. Indeed, in vitro studies show that telomeres can 
lengthen activated B cell telomere length increases as 
these cells multiply in germinal centers in response to 
pathogenic challenge [3].  TLC in part reflects the 
balance between telomere elongation by telomerase 
action versus telomere shortening processes.   
 
Cellular senescence may underlie the progression of 
diseases associated with organismic aging [4].  Mice 
bred without telomerase develop shorter telomeres, and 
show premature aging, including hair graying, impaired 
wound healing, reduced proliferation of lymphocytes, 
and, in later generations, early mortality and infertility 
[5].  Humans with a rare genetic disorder (dyskeratosis 
congenita) that leads to half the effective gene dosage of 
telomerase show early mortality and increased 
incidences of fibrosis, cancer, progressive bone marrow 
failure and other indications of premature aging; other 
premature aging syndromes are also often characterized 
by shortened telomeres [4, 6-8].  Despite these lines of 
evidence, among the general population of healthy 
humans without pathologic premature aging syndromes, 
little direct data exist to link cellular aging with 
organismic aging. 
 
The strongest evidence that cellular aging, as reflected 
by shorter telomeres, might be associated with 
organismic aging has until now been derived from cross 
sectional studies.  Shorter telomere length (TL) in 
leukocytes has been associated cross-sectionally with 
CVD and its risk factors, including pulse pressure [9-
11], obesity [12, 13], vascular dementia [14], diabetes 
[13, 15, 16], CAD [17], and myocardial infarction [18] 
although not in all studies [19].   TL has also been 
shown to predict CVD events (MI and stroke) in men 
under 73 years old [20].  Cawthon and colleagues found 
that TL predicted earlier mortality, particularly from 
CVD and infectious disease, in a sample of 143 healthy 
men and women 60 years and older [21].  This suggests 
that poor telomere maintenance may serve as a 
prognostic biomarker of risk of early mortality.  Since 
then, additional studies  have found blood TL predicts 
mortality, in large twin studies [22, 23], and in 
Alzheimers [24], and stroke patients [25]. However, 
other reports, notably those with very elderly cohorts, 
have failed to find an association between TL and 
mortality [26].  
A single TL assessment, however, leaves open the 
possibility that TL at birth, rather than rate of telomere 
attrition, accounts for this association with mortality.  
One might have expected, given the low rate of attrition 
throughout life, that TL at birth would be a strong 
predictor of TL later in life. However, twin studies 
indicate non-genetic factors can have significant effects 
on telomere length later in life; telomere length was 
similarly related in identical compared to fraternal male 
twins over 70 years old, suggesting a large non-genetic 
influence [27], and identical twins who exercised had 
longer leukocyte telomeres than the identical twin who 
did not [28].  Further, twin studies show that telomere 
length predicts mortality beyond genetic influences [22, 
23].   Hence, longitudinal studies that examine telomere 
changes over time within individuals are needed to test 
the prognostic value of the rate of telomere length 
change (TLC). 
 
In one of the only published studies of TLC over time in 
humans, a study of 70 adults found that a small 
percentage (10%) of subjects showed leukocyte 
telomere length maintenance or lengthening over a ten 
year period [12]. No studies we are aware of in humans 
have systematically examined TLC within a short 
period of only a few years, and how this may or may 
not be linked to subsequent mortality.  The current 
study examined TL and TLC in a high functioning 
sample of 70-79 year olds.  We aimed to: 1) Describe 
the natural history of telomere length change over a 2.5 
year period in a sample of elderly men and women; and 
2) Test TL and particularly TLC as predictors of 
mortality.  Lastly, we explored whether the combination 
of short TL and greater TLC predicted greater risk of 
subsequent mortality than either one indicator alone.  
We report here that TLC over the next 2.5 years did 
indeed predict 12-year mortality from cardiovascular 
disease in men. Hence we propose that the rate of 
leukocyte telomere shortening is a potentially useful 






The participants were aged 70 to 79 at baseline (1988), 
with an average age of 73.7 years (SD = 2.87).  Their 
ethnicity was Caucasian (100%).  The average BMI, 
blood pressure, alcohol intake, physical activity, and 
percent of smokers and of those with diabetes are 
shown in Table 1.  We also examined sociodemo-
graphic and health variables by short and long TL 
groups.  As shown in Table 1, there were no group 
differences in any of the sociodemographic or health 
variables examined by long and short TL groups.   
  


































Further, we examined these factors in TL groups by sex, 
and still found no significant differences across the 
groups (men with long vs. short TL, and women with 
long vs. short TL). 
 
 
Natural history of Telomere Length Change 
(TLC) over 2.5 years 
 
The average baseline TL was 1.1 t/s (4697 base pairs or 
bp), and ranged from 0.46 to 1.9 t/s.  Consistent with 
other studies, women had longer TL at baseline (mean 
t/s 1.17; SD = .233) , compared to men (mean t/s 1.09; 
SD = .233, p < .008). Hence, when TL was divided into 
long and short, based on a median split for the entire 
sample of men plus women, there tended to be  more 
women in the long telomere group (58.3% women), and 
more men in the short telomere length group (56.7% 
men). The mean TL at the follow-up visit 2.5 years after 
baseline was similar, (mean t/s 1.1; with a range from 
0.76 to 1.8). The raw t/s change score values ranged 
from -.75 to .60.  This corresponds to a range from a net 
loss of 1067 bp/year to a net gain of 925 bp/year, at the 




N = 235 
Short TL* 
N = 117 
Long TL 
N  = 118 
T/S ratio 1.1 (0.24) 0.94 (0.13) 
a 
1.3 (0.16)  
Mean Age 73.7 (2.9) 73.7 (2.9) 73.7 (2.9) 
Mean Education 
(years) 
10.5 (2.5) 10.6 (2.5) 10.4 (2.6) 
Mean Diastolic BP 75.4 (10.1) 74.7 (10.0) 76.0 (10.2) 




Hypertension (%) 49.4 47.9 50.9 
Diabetes (%) 20.4 22.4 18.3 
Mean Physical 
Activity 
18.9 (25.5) 21.3 (27.3) 16.4 (23.4) 




4.5 (11.1) 4.5 (9.9) 4.5 (12.2) 
 






and  behavioral  factors    by  TL  group,  above,  or  by  sex  and  TL 
group (not shown).  
 
To quantify the extent of more substantial (and likely 
more meaningful) decreases or increases in TL, we 
categorized people based on change scores that were 
outside the 7% range of the variability expected for the 
assay.  To be conservative, we used differences of at 
least +/- 15% from the baseline TL value as a cut point 
for indicating a reliable and large change from baseline.  
Participants who showed less than a 15% change 
(increase or decrease) from their baseline TL were 
categorized as TL Maintainers. TL maintainers 
comprised 46% of the sample.  For the purposes of this 
analysis, those who showed a decrease in TL of greater 
than 15% are described as having significant shortening, 
and comprised 30% of the sample.  Those with greater 
than 15% increase in TL are described as having 
significant lengthening, and were 24% of the sample.   
 
Predictors of %TLC 
 
Spearman correlations with %TLC were performed for 
several candidate sociodemographic and self reported 
health behaviors. There were no consistent patterns and 
correlations were weak, as follows:  Age (within the 
narrow 70-79 year baseline age span for this cohort) 
was not related to TL or %TLC for women, but was 
related to greater %TLC for men (r = -.27, p < .05), in 
that older men showed greater rates of telomere 
attrition.  Higher BMI was related to greater %TLC 
(greater decreases) in women (rho = -.25, p < .05), but 
not significantly for men (rho = -.12, ns).  Alcohol use 
was also related to greater %TLC (greater decreases), 
again in women only (rho = -.31, p < .05).  TL and 
%TLC were not associated with education (rho = -.01, 
ns), pack years of cigarettes (rho = -.04, ns), or physical 










  Men Women 
Baseline TL Short  25.8%  29.4% * 
Long  24.0%  13.2% 
TL Change  Shortened  46.7% *  16.7% 
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Do TL or %TLC predict mortality? 
 
By 2000 (12 years from the beginning of the study), 102 
(43.4%) participants were known to have died, 
according to death certificates (42 women, 60 men). 
There were no associations of TL or %TLC on overall 
12 year mortality. We then examined mortality from 
different causes in relation to leukocyte TL or telomere 
length change. There were not enough deaths due to 
infectious disease (n = 6) to examine independently. 
More than half of deaths (53) were from cardiovascular 
disease (24 women, 29 men), the main outcome in this 
study.   CVD mortality rates by gender for baseline TL 
and %TLC are listed in Table 2.   For the sample as a 
whole (men and women combined), baseline TL weakly 
predicted CVD mortality, a relationship which achieved 
only marginal statistical significance, p < .10. This trend 
is consistent with Cawthon’s previous study (2003).  
However, when we examined the sample by gender, 
women with shorter baseline TL were 2.3 times more 
likely to die from CVD over the next 12 years compared 
with those with longer baseline TL (95% CI = 1.0 – 5.3, 
p < 0.05, Table 3, Figure 1).  Specifically, 20% of 
women had died from CVD, and of these, the majority 
(62.5%) were in the short TL group.  This effect held 
only for women, with no association of TL with CVD 
mortality for men (p = .60).  Although not significant, 
Cawthon et al (2003) also found a marginally stronger 
effect of TL on mortality for women as compared with 
men.   
 
We next examined rate of telomere shortening (%TLC), 
categorically, in relation to subsequent mortality, 
comparing those in the lowest quartile of %TLC 
(representing those with the greatest shortening) to the 
rest of the sample.  For women, there was no 
association of 12 year CVD mortality with the rate of 
TL shortening during the 2.5 years monitored at the 
beginning of the 12 year period (p = .98).  Strikingly, 
TL shortening rate in the men was linked to greater 
CVD mortality (hazard ratio = 3.0, 95% CI = 1.1 – 8.2, 
p < .04, Table 3, Figure 2).    
 
A final set of secondary analyses examined the 
combined impact of having both shorter baseline TL 
and experiencing a decline in TL over time on CVD 
mortality and overall mortality. Given the strong 
relation between baseline TL and change in TL, with 
greater shortening seen in those with longer rather than 
shorter baseline TL, there were insufficient numbers of 
participants who had both short TL and shortening over 
time when examining CVD mortality. When examining 
overall mortality, there were nine participants in the 
both short baseline and shortening over time category.  
A Chi Square testing baseline TL (long vs. short) by 
change (shortening vs. no shortening) by mortality was 
significant, X2 (3) = 8.70, p < .03. The men with short 
baseline TL and maintenance or lengthening over time 
were more likely to be alive 12 years later (20 of 29, 
69%), compared to those with short baseline TL and 
telomere shortening (1 of 8, 13%).    In contrast, for 
men with relatively long baseline telomeres, there was 
no apparent effect of rate of shortening on mortality: 
those with telomere lengthening over time tended to be 
equally likely to be alive 12 years later (40%), 










Telomere maintenance has emerged as a significant 
determinant of the ability of mitotic cells to continue 
proliferating [29].   Cawthon et al. (2003) have pre-
viously shown in a cross sectional study that telomere 
length in late human adulthood can predict longevity.  
Here we extend and replicate these findings: we  found 
that in older women, short telomere length (below 
average baseline TL) was associated with almost three 
times the risk of 12-year mortality from cardiovascular 
disease compared to women with longer baseline TL.  
Further, we report a novel association of failure to 
maintain telomere length with cardiovascular disease 
mortality; we found that men who showed leukocyte 
telomere shortening over the short period of 2.5 years 
were subsequently three times more likely to die from 
Figure 1.  Those with shorter  (below median) telomere  length
at  baseline  (dashed  line)  had  2.3 times  greater  likelihood  of
mortality  over  the  following  12  years  compared  to  those with
longer telomeres (solid line). 
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heart disease than those who maintained leukocyte 
telomere length. Exploratory analyses also found that 
among men, those with both shorter baseline TL and 
shortening over the 2.5 year interval (though only a 
small subset of the total sample) had extremely high 12-
year mortality (87%), as compared to men who also had 
short baseline telomeres, but who showed stable 
maintenance or lengthening of their telomeres during 
this period (31%).  Given the small sample size this 
secondary analysis must be replicated.    
 
What factors might lead to faster telomere shortening? 
Telomere shortening, especially in the face of already 
short telomeres, is indicative of insufficient telomerase, 
as cells with short telomeres, but with adequate 
telomerase, can maintain proliferation and longevity [5, 
30].  Thus, it is in part the co-occurrence of short 
telomeres and low telomerase activity that appears to 
increase the risk of cell death in vitro [31].  More 
specifically, in relation to CVD, telomerase is crucial 
for healthy cardiovascular cell functioning [32], and has 
been linked to cardiovascular disease risk factors in 
vivo [33].  We speculate that low telomerase, as 
indicated by the rate of telomere shortening, may also 
have contributed to the more rapid decline in 
cardiovascular health and subsequent earlier mortality 
observed in men.   
 Another interesting finding was that in general, people 
in this study with short leukocyte telomeres tended to 
have a slower rate of telomere shortening over time, 
compared to those with longer telomeres.  This relation 
between telomere length and change in telomere length 
was strong (r = -.71).  Such a finding is consistent with 
the available information about telomerase action and 
the consequences of telomere shortening in cells, in 
which telomerase preferentially elongates shorter rather 
than the longer telomeres [31, 34], and cells with 
critically short telomeres become underrepresented in 
the cell population because they cease to proliferate.  
This inverse relationship also underscores the potential 
importance of adjusting for baseline telomere length 
when examining rate of change, since we found the two 
are strongly inversely related.  One untested possibility 
for this inverse relationship is that people with short 
telomeres may have upregulated telomerase, which 
would lead to less attrition per replication, and thus 
prevent loss of telomere length over years.  However, 
there is likely to be strong selection for those cells in 
vivo that have maintained telomeres above critically 
short lengths, and thus there may be an in vivo selection 
for cells with short telomeres that also have higher 
levels of telomerase.  These are all salient questions for 
future research.  
It is notable that cross-sectional TL did predict mortality 
in this sample of women, given their older age (70 to 79 
years old).  This is consistent with two population-based 
twin studies examining cross-sectional telomere length 
in people of this age range or older [22, 23]  but 
discrepant with four studies, which have found weaker 
[21] or no [26, 35, 36] effects for mortality in 
participants over 70 years old.  The present study used a 
subset of participants from the MacArthur Study of 
Successful Aging, which only enrolled participants with 
good cognitive and physical functioning.  In this 
respect, it is an atypical sample of elderly people, who 
are possibly biologically younger than the unselected 
elderly samples typically studied. This may explain why 
TL served as a predictor in this elderly sample but not 
in other elderly samples.   Further, selection bias for 
healthy elderly men in the present study may in part 
account for why cross-sectional TL in men did not 
predict mortality in men, as it did in women.  Men who 
are very healthy at 70 to 80 years old (as in this study) 
are likely even more highly selected than the women 
given the higher mortality rates for men [37].  Thus they 
may be more selected for having some underlying 
resiliency toward age-related diseases than would be 














Figure  2.    Those  with  telomere  shortening  over  a  2.5  year
period  (dashed  line)  had  3.0  times  greater  likelihood  of
mortality  over  the  12  years  since  the  baseline  blood  draw,
compared to those without telomere shortening (solid line). 
 
The mechanism by which peripheral blood leukocyte 
telomere shortening may be linked to mortality is not 
yet understood.  Leukocyte telomere length may serve 
as a proxy for whole body aging or cardiovascular 
aging, because leukocyte telomere length has been 
correlated with telomere length in other tissues [14, 38].  
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Leukocyte telomere length may also serve as a proxy 
for biochemical stress, such as oxidative stress and 
inflammation, known to both shorten telomeres and 
contribute to CVD [39]. Both alcohol excess and 
obesity are thought to create a milieu of oxidative stress 
[40, 41]. Indeed, among women in the current study, 
greater obesity and alcohol use and obesity at baseline 
were related to greater telomere attrition rate. The 
finding with obesity is consistent with other studies 
which have found concurrent cross-sectional 
relationships between BMI and TL [13].  Alcohol use 
has not been previously linked to telomere length. 
 
Lastly, leukocyte telomere shortening has important 
functional consequences that may contribute directly to 
the pathogenesis of CVD.  Short telomeres lead to 
cessation of cell division and can elicit cell death and, in 
the absence of fully functional cellular damage 
checkpoints, can lead to genomic instability via end-to-
end chromosome fusions [5, 6, 31]. When telomeres 
become critically shortened in leukocytes, these cells 
become senescent and secrete pro-inflammatory 
cytokines [42, 43].   Thus, a senescent immune system 
can contribute to a pro-inflammatory milieu, and 
senescent macrophages can contribute directly to 
atherosclerotic plaques [32].  
 
 While such mechanistic pathways are yet to be 
elucidated, our findings suggest that telomere rate of 
change may be an important predictor of human 
longevity.  Rate of attrition is informative in that it may 
reflect genetic, biological, and lifestyle (behavioral) 
factors.  This study suggests the possibility that 
telomere length changes over the short term might be a 
clinically useful measure of health status and risk.  
However, this study is limited in that we cannot infer 
causality, and the findings need replication from larger 
samples before TLC is considered a validated predictor 




MATERIALS AND METHODS 
 
Participants and procedures.  Participants were men and 
women, from a population-based sample in East Boston 
(one site of the three-site MacArthur Study of 
Successful Aging).  Subjects were selected from within 
a larger population-based NIA-funded cohort study by a 
score in the upper tertile on six markers of mental and 
physical health, as described in detail in elsewhere [44] 
and all provided written informed consent.  This study 
received approval from an institutional review board at 
each site and was conducted in accordance with the 
1964 Declaration of Helsinki (see The World Medical 
Association: The Declaration of Helsinki 
www.wma.net/e/policy/b3htm) and International 
Conference on Harmonization/Good Clinical Practice 
guidelines. Written informed consent was obtained from 
each patient before participation.  
 
Though they had good cognitive and physical function, 
they could have chronic disease.  Response rates were 
over 90%.   Men (N=116) and women (n=120) were 
randomly sampled from among the approximately 800 
with available baseline (1988) and follow-up (1991) 
DNA.   Blood was drawn at various times of day on the 
baseline visit, and on a follow-up visit for 134 
participants, 2.5 years later (1991), including 66 men 
and 68 women.  Buffy coat was stored at -800C.  DNA 
was later extracted at the UCLA General Clinical 
Research Center (Los Angeles), frozen, and shipped to 
Dr. Cawthon’s laboratory (University of Utah) for TL 
assays (see below).  
 
Statistical analyses. We first examined the relation 
between TL and TLC variables to see which measure of 
TLC was most independent of baseline TL.  Spearman 
correlation was performed between TL and %TLC (rho 
= -.71, p < .0001).  The correlation between TL and raw 
TLC (rather than % change) was similarly large  (rho = 
 -.66, p < .0001):  Those with longer TL at baseline 
showed greater rate of change (shortening), and 
conversely, those with shorter TL at baseline showed 
slower rate of change (less shortening or more 
lengthening). In light of this, we chose percent change 
(vs. a raw change score) as the measure of change 
independent of baseline length because it adjusts for 
baseline TL, and hence percent of telomere length 
change (%TLC) was used in all analyses. 
  Men Women 
Baseline 
TL 
Short  1.2 (0.6-2.6) 2.3 (1.0-5.3)* 
Long Reference Reference 
TL 
Change  
Shortened 3.0 (1.1-8.2)* 1.0 (0.3-3.7)  






TL and %TLC were used as continuous variables.  To 
examine correlates of TL and %TLC, Spearman rank 
order correlations were used.  To examine whether TL 
and %TLC were predictors of mortality, Cox 
Proportional Hazards analyses were used, using survival 
time calculated in days.    TL and %TLC were also exa-
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mined as categorical variables - baseline TL (short or 
long, based on a median split) and shortening over time 
(yes or no, with shortening reflecting the lowest most 
negative 25 percent ile of change).   Lastly, given 
known gender differences in TL and mortality, all 
analyses were done across the group and also by gender.   
 
Telomere length assay. Blood was drawn in subject’s 
home and processed soon after.  Buffy coat was stored 
at -800C.  DNA was extracted by the UCLA GCRC, 
with Gentra system kits.  Telomere length was 
measured from DNA using a PCR-based assay as 
follows:   Two quantitative PCR reactions were 
performed in separate reactions, consisting of an 
amplification of telomere sequence (T), and of a 
specific single copy gene in the genome (S). The ratio 
of T/S corresponds to telomere length, when multiplied 
by a standardization factor.  The conversion factor from 
t/s to base pairs (bp) for this study is 4270.  All assays 
were performed in duplicate, have high reliability and 
validity [45], and have been used in multiple prior 
studies [21, 24].   
 
Telomere length, as measured by T/S ratio, was 
normally distributed, with a skew of 0.33 and kurtosis 
0.14. TLC was calculated as both raw change (TL2 
minus TL1), and a percent change   ((TL2-
TL1)*100)/TL1, and categorically into TL change 
groups, as described below.  We excluded one subject 
with a change in telomere length greater than four 
standard deviations from the mean, making the final 
sample size 235.   
 
Mortality. Twelve-year mortality data (from 1988 to 
2000) were obtained from a National Death Index 
search that provided date and cause of death 
information based on death certificate data.  Data on 
overall mortality and CVD mortality were used here. 
 
Health behaviors and indices. Smoking was measured 
by pack-years (average reported packs/day * years 
smoked).  Alcohol consumption was measured based on 
participants’ reports of how much beer, wine and hard 
liquor they usually consume per month, and then 
converted to an average monthly quantity of ethyl 
alcohol consumed. Physical activity was measured as 
the sum of reported participation in strenuous work 
activities and strenuous recreational activities.  The 
detailed measures are described in Seeman et al, 1995 
[46].  Height and weight were based on self report.  
BMI was calculated as weight/height2 in kg/m2.  Blood 
pressure was measured as the average of two resting, 
seated assessments. Presence of diabetes was 
determined by self report. 
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